Further understanding of the immunopathology of multiple sclerosis: impact on future treatments

Expert Review of Clinical Immunology

Volumn 12, Issue 10, 2016, Pages 1069-1089

  Bhise, Vikram ^a   Dhib Jalbut, Suhayl ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

demyelination; immune therapies; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; ANTIGEN; BETA INTERFERON; CD20 ANTIBODY; CYTOKINE; DACLIZUMAB; GAMMA INTERFERON; GLATIRAMER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 1BETA; LAQUINIMOD; MATRIX METALLOPROTEINASE; MITOCHONDRIAL DNA; MONOCLONAL ANTIBODY; MYELIN; NATALIZUMAB; TUMOR NECROSIS FACTOR; VITAMIN D; AUTOANTIBODY;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DEMYELINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENETIC RISK; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; IMMUNOTHERAPY; INFLAMMATORY CELL; INNATE IMMUNITY; INTESTINE FLORA; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOZYGOTIC TWINS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; REGULATORY T LYMPHOCYTE; RELAPSE; REMISSION; REMYELINIZATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; VACCINATION; VITAMIN D DEFICIENCY; WESTERN DIET; WHITE MATTER; ANIMAL; B LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; IMMUNOLOGY; METABOLISM; PROCEDURES; T LYMPHOCYTE; TRENDS;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; CYTOKINES; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 84987942213     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1080/1744666X.2016.1191351     Document Type: Review

References (379)

1. R.Hohlfeld, H.Wekerle Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy:from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A. 2004 Oct 5;101(Suppl 2):14599–14606.
2. H.Lassmann. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci. 2013 Oct 15;333(1–2):1–4.
3. R.Weissert. The immune pathogenesis of multiple sclerosis. J NeuroImmune Pharmacol. 2013 Sep;8(4):857–866.
4. C.J.Mumford, N.W.Wood, H.Kellar-Wood, et al. The British Isles survey of multiple sclerosis in twins. Neurology. 1994 Jan;44(1):11–15.
5. P.A.Gourraud, H.F.Harbo, S.L.Hauser, et al. The genetics of multiple sclerosis:an up-to-date review. Immunol Rev. 2012 Jul;248(1):87–103.
6. D.A.Hafler, A.Compston, S.Sawcer, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007 Aug 30;357(9):851–862.
7. S.Sawcer, G.Hellenthal, M.Pirinen, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 Aug 11;476(7359):214–219.
8. A.H.Beecham, N.A.Patsopoulos, D.K.Xifara, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013 Nov;45(11):1353–1360.
9. J.L.Huynh, P.Casaccia. Epigenetic mechanisms in multiple sclerosis:implications for pathogenesis and treatment. Lancet Neurol. 2013 Feb;12(2):195–206.
10. J.A.Ellis, A.S.Kemp, A.L.Ponsonby. Gene-environment interaction in autoimmune disease. Expert Rev Mol Med. 2014;16:e4.
11. D.Miljkovic, I.Spasojevic. Multiple sclerosis:molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2013 Dec 20;19(18):2286–2334.
12. I.Metz, S.D.Weigand, B.F.Popescu, et al. Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol. 2014 May;75(5):728–738.
13. C.F.Lucchinetti, B.F.Popescu, R.F.Bunyan, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011 Dec 8;365(23):2188–2197.•• An excellent paper on cortical lesions and meningeal inflammation.
14. M.T.Fischer, I.Wimmer, R.Hoftberger, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain J Neurol. 2013 Jun;136(Pt 6):1799–1815.
15. H.Kebir, I.Ifergan, J.I.Alvarez, et al. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol. 2009 Sep;66(3):390–402.
16. R.E.Gonsette. Self-tolerance in multiple sclerosis. Acta Neurol Belg. 2012 Jun;112(2):133–140.
17. C.Camperio, M.Muscolini, E.Volpe, et al. CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes. Immunol Lett. 2014 Mar–Apr;158(1–2):134–142.
18. J.Haas, B.Fritzsching, P.Trubswetter, et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol. 2007 Jul 15;179(2):1322–1330.
19. F.Carbone, V.De Rosa, P.B.Carrieri, et al. Regulatory T cell proliferative potential is impaired in human autoimmune disease. Nat Med. 2014 Jan;20(1):69–74.
20. T.Kinnunen, N.Chamberlain, H.Morbach, et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest. 2013 Jun;123(6):2737–2741.
21. J.I.Alvarez, O.Saint-Laurent, A.Godschalk, et al. Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions. Neurobiol Dis. 2015;74:14–24.
22. E.Bettelli, Y.Carrier, W.Gao, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006 May 11;441(7090):235–238.
23. M.Veldhoen, R.J.Hocking, C.J.Atkins, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006 Feb;24(2):179–189.
24. L.Zhou, I.I.Ivanov, R.Spolski, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007 Sep;8(9):967–974.
25. K.Ghoreschi, A.Laurence, X.P.Yang, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature. 2010 Oct 21;467(7318):967–971.
26. L.Codarri, G.Gyulveszi, V.Tosevski, et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol. 2011 Jun;12(6):560–567.
27. J.E.Mindur, N.Ito, S.Dhib-Jalbut, et al. Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE. PLoS One. 2014;9(6):e99068.
28. S.Rolla, V.Bardina, S.De Mercanti, et al. Th22 cells are expanded in multiple sclerosis and are resistant to IFN-beta. J Leukoc Biol. 2014 Dec;96(6):1155–1164.
29. V.Annibali, G.Ristori, D.F.Angelini, et al. CD161(high)CD8+T cells bear pathogenetic potential in multiple sclerosis. Brain J Neurol. 2011 Feb;134(Pt 2):542–554.
30. F.Lolli, H.Martini, A.Citro, et al. Increased CD8+ T cell responses to apoptotic T cell-associated antigens in multiple sclerosis. J Neuroinflammation. 2013;10:94.
31. D.F.Angelini, B.Serafini, E.Piras, et al. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9(4):e1003220.
32. R.Yamasaki, H.Lu, O.Butovsky, et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med. 2014 Jul 28;211(8):1533–1549.
33. J.Van Horssen, S.Singh, S.Van Der Pol, et al. Clusters of activated microglia in normal-appearing white matter show signs of innate immune activation. J Neuroinflammation. 2012;9:156.
34. S.Singh, I.Metz, S.Amor, et al. Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. Acta Neuropathol. 2013 Apr;125(4):595–608.
35. J.N.Stern, G.Yaari, J.A.Vander Heiden, et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med. 2014 Aug 6;6(248):248ra107.
36. G.Disanto, J.M.Morahan, M.H.Barnett, et al. The evidence for a role of B cells in multiple sclerosis. Neurology. 2012 Mar 13;78(11):823–832.• A nice review of B cell mechanisms in MS.
37. N.Molnarfi, U.Schulze-Topphoff, M.S.Weber, et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. 2013 Dec 16;210(13):2921–2937.
38. R.P.Lisak, J.A.Benjamins, L.Nedelkoska, et al. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol. 2012 May 15;246(1–2):85–95.
39. L.L.Aung, M.M.Mouradian, S.Dhib-Jalbut, et al. MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a. J Neuroimmunol. 2015 Jan 15;278:185–189.
40. R.Srivastava, M.Aslam, S.R.Kalluri, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012 Jul 12;367(2):115–123.
41. M.Sospedra, R.Martin. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683–747.
42. D.Mahad, I.Ziabreva, H.Lassmann, et al. Mitochondrial defects in acute multiple sclerosis lesions. Brain J Neurol. 2008 Jul;131(Pt 7):1722–1735.
43. D.J.Mahad, I.Ziabreva, G.Campbell, et al. Mitochondrial changes within axons in multiple sclerosis. Brain J Neurol. 2009 May;132(Pt 5):1161–1174.
44. M.E.Witte, L.Bo, R.J.Rodenburg, et al. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol. 2009 Oct;219(2):193–204.
45. N.Ohno, H.Chiang, D.J.Mahad, et al. Mitochondrial immobilization mediated by syntaphilin facilitates survival of demyelinated axons. Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9953–9958.
46. J.S.Kang, J.H.Tian, P.Y.Pan, et al. Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation. Cell. 2008 Jan 11;132(1):137–148.
47. J.L.Zambonin, C.Zhao, N.Ohno, et al. Increased mitochondrial content in remyelinated axons:implications for multiple sclerosis. Brain J Neurol. 2011 Jul;134(Pt 7):1901–1913.
48. J.Correale, M.C.Ysrraelit, M.I.Gaitan. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain J Neurol. 2009 May;132(Pt 5):1146–1160.
49. J.Correale, M.C.Ysrraelit, M.I.Gaitan. Vitamin D-mediated immune regulation in multiple sclerosis. J Neurol Sci. 2011 Dec 15;311(1–2):23–31.
50. R.M.Lucas, A.L.Ponsonby, K.Dear, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology. 2011 Feb 8;76(6):540–548.
51. K.Bjornevik, T.Riise, I.Casetta, et al. Sun exposure and multiple sclerosis risk in Norway and Italy:the EnvIMS study. Mult Scler. 2014 Jan 10;20(8):1042–1049.
52. R.Dobson, G.Giovannoni, S.Ramagopalan. The month of birth effect in multiple sclerosis:systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013 Apr;84(4):427–432.
53. H.Tremlett, I.A.Van Der Mei, F.Pittas, et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology. 2008;31(4):271–279.
54. A.Ascherio, K.L.Munger, R.White, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014 Mar;71(3):306–314.
55. M.Kongsbak, M.R.Von Essen, T.B.Levring, et al. Vitamin D-binding protein controls T cell responses to vitamin D. BMC Immunol. 2014;15:35.
56. A.Tian, H.Ma, X.Cao, et al. Vitamin D improves cognitive function and modulates Th17/T reg cell balance after hepatectomy in mice. Inflammation. 2015 Apr;38(2):500–509.
57. K.L.Munger, K.Kochert, K.C.Simon, et al. Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Annals Clin Transl Neurol. 2014 Aug;1(8):605–617.
58. B.Kalman, E.Toldy. Genomic binding sites and biological effects of the vitamin D–VDR complex in multiple sclerosis [corrected]. Neuromolecular Med. 2014 Jun;16(2):265–279.
59. S.Kvistad, K.M.Myhr, T.Holmoy, et al. Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Mult Scler. 2014 Dec;20(14):1833–1840.
60. E.Jaquiery, S.Jilek, M.Schluep, et al. Intrathecal immune responses to EBV in early MS. Eur J Immunol. 2010 Mar;40(3):878–887.
61. H.Irizar, M.Munoz-Culla, L.Sepulveda, et al. Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progression. PLoS One. 2014;9(2):e90482.
62. B.Serafini, M.Severa, S.Columba-Cabezas, et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain:implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol. 2010 Jul;69(7):677–693.
63. B.Serafini, B.Rosicarelli, D.Franciotta, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007 Nov 26;204(12):2899–2912.
64. S.A.Sargsyan, A.J.Shearer, A.M.Ritchie, et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology. 2010 Apr 6;74(14):1127–1135.
65. S.N.Willis, C.Stadelmann, S.J.Rodig, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain J Neurol. 2009 Dec;132(Pt 12):3318–3328.
66. L.A.Peferoen, F.Lamers, L.N.Lodder, et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain J Neurol. 2010 May;133(Pt 5):e137.
67. O.Torkildsen, C.Stansberg, S.M.Angelskar, et al. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathol. 2010 Jul;20(4):720–729.
68. J.S.Tzartos, G.Khan, A.Vossenkamper, et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology. 2012 Jan 3;78(1):15–23.
69. B.Serafini, L.Muzio, B.Rosicarelli, et al. Radioactive in situ hybridization for Epstein-Barr virus-encoded small RNA supports presence of Epstein-Barr virus in the multiple sclerosis brain. Brain J Neurol. 2013 Jul;136(Pt 7):e233.
70. M.P.Pender. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 2003 Nov;24(11):584–588.
71. M.P.Pender, P.A.Csurhes, C.M.Pfluger, et al. Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis. Mult Scler. 2014 Dec;20(14):1825–1832.
72. A.C.Van Sechel, J.J.Bajramovic, M.J.Van Stipdonk, et al. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol. 1999 Jan 1;162(1):129–135.
73. H.L.Lang, H.Jacobsen, S.Ikemizu, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol. 2002 Oct;3(10):940–943.
74. C.Mancao, W.Hammerschmidt. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood. 2007 Nov 15;110(10):3715–3721.
75. J.Rastelli, C.Homig-Holzel, J.Seagal, et al. LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood. 2008 Feb 1;111(3):1448–1455.
76. A.Ascherio, K.L.Munger. Environmental risk factors for multiple sclerosis. Part I:the role of infection. Ann Neurol. 2007 Apr;61(4):288–299.• A great review on the contribution of viruses to the risk of developing MS.
77. N.Makhani, B.Banwell, R.Tellier, et al. Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Mult Scler. 2016 Mar;22(3):385–388.
78. E.Sundqvist, T.Bergstrom, H.Daialhosein, et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult Scler. 2014 Feb;20(2):165–173.
79. E.Waubant, E.M.Mowry, L.Krupp, et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology. 2011 Jun 7;76(23):1989–1995.
80. E.Meinl, M.Krumbholz, R.Hohlfeld. B lineage cells in the inflammatory central nervous system environment:migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol. 2006 Jun;59(6):880–892.
81. A.K.Hedstrom, J.Hillert, T.Olsson, et al. Smoking and multiple sclerosis susceptibility. Eur J Epidemiol. 2013 Nov;28(11):867–874.
82. J.Salzer, G.Hallmans, M.Nystrom, et al. Smoking as a risk factor for multiple sclerosis. Mult Scler. 2013 Jul;19(8):1022–1027.
83. S.A.Roudbari, M.M.Ansar, A.Yousefzad. Smoking as a risk factor for development of secondary progressive multiple sclerosis:a study in IRAN, Guilan. J Neurol Sci. 2013 Jul 15;330(1–2):52–55.
84. Z.Gao, J.C.Nissen, K.Ji, et al. The experimental autoimmune encephalomyelitis disease course is modulated by nicotine and other cigarette smoke components. PLoS One. 2014;9(9):e107979.
85. J.Correale, M.F.Farez. Smoking worsens multiple sclerosis prognosis:two different pathways are involved. J Neuroimmunol. 2015 Apr;15(281):23–34.
86. K.C.Simon, I.A.Van Der Mei, K.L.Munger, et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology. 2010 Apr 27;74(17):1365–1371.
87. A.K.Hedstrom, I.L.Bomfim, L.F.Barcellos, et al. Interaction between passive smoking and two HLA genes with regard to multiple sclerosis risk. Int J Epidemiol. 2014 Dec;43(6):1791–1798.
88. A.K.Hedstrom, E.Sundqvist, M.Baarnhielm, et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain J Neurol. 2011 Mar;134(Pt 3):653–664.
89. C.O’Gorman, S.A.Broadley. Smoking and multiple sclerosis:evidence for latitudinal and temporal variation. J Neurol. 2014 Sep;261(9):1677–1683.
90. Y.Arnson, Y.Shoenfeld, H.Amital. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010 May;34(3):J258–65.
91. J.Lee, V.Taneja, R.Vassallo. Cigarette smoking and inflammation:cellular and molecular mechanisms. J Dent Res. 2012 Feb;91(2):142–149.
92. F.Odoardi, C.Sie, K.Streyl, et al. T cells become licensed in the lung to enter the central nervous system. Nature. 2012 Aug 30;488(7413):675–679.
93. A.Manzel, D.N.Muller, D.A.Hafler, et al. Role of “Western diet” in inflammatory autoimmune diseases. Curr Allergy Asthma Rep. 2014 Jan;14(1):404.
94. K.L.Munger, T.Chitnis, A.Ascherio. Body size and risk of MS in two cohorts of US women. Neurology. 2009 Nov 10;73(19):1543–1550.
95. K.L.Munger, J.Bentzen, B.Laursen, et al. Childhood body mass index and multiple sclerosis risk:a long-term cohort study. Mult Scler. 2013 Sep;19(10):1323–1329.
96. A.Langer-Gould, S.M.Brara, B.E.Beaber, et al. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology. 2013 Feb 5;80(6):548–552.
97. M.A.Gianfrancesco, B.Acuna, L.Shen, et al. Obesity during childhood and adolescence increases susceptibility to multiple sclerosis after accounting for established genetic and environmental risk factors. Obes Res Clin Pract. 2014 Sep–Oct;8(5):e435–47.
98. S.Emamgholipour, S.M.Eshaghi, A.Hossein-nezhad, et al. Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis:a possible link to susceptibility and clinical course of disease. PLoS One. 2013;8(10):e76555.
99. M.Kleinewietfeld, A.Manzel, J.Titze, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature. 2013 Apr 25;496(7446):518–522.
100. M.F.Farez, M.P.Fiol, M.I.Gaitan, et al. Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):26–31.
101. L.Piccio, J.L.Stark, A.H.Cross. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. J Leukoc Biol. 2008 Oct;84(4):940–948.
102. A.I.Esquifino, P.Cano, V.Jimenez-Ortega, et al. Immune response after experimental allergic encephalomyelitis in rats subjected to calorie restriction. J Neuroinflammation. 2007;4:6.
103. S.Timmermans, J.F.Bogie, T.Vanmierlo, et al. High fat diet exacerbates neuroinflammation in an animal model of multiple sclerosis by activation of the Renin Angiotensin system. J NeuroImmune Pharmacol. 2014 Mar;9(2):209–217.
104. S.Winer, G.Paltser, Y.Chan, et al. Obesity predisposes to Th17 bias. Eur J Immunol. 2009 Sep;39(9):2629–2635.
105. V.Sanna, A.Di Giacomo, A.La Cava, et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest. 2003 Jan;111(2):241–250.
106. A.K.Hedstrom, I.Lima Bomfim, L.Barcellos, et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology. 2014 Mar 11;82(10):865–872.
107. Y.Belkaid, T.W.Hand. Role of the microbiota in immunity and inflammation. Cell. 2014 Mar 27;157(1):121–141.
108. K.Telesford, J.Ochoa-Reparaz, L.H.Kasper. Gut commensalism, cytokines, and central nervous system demyelination. J Interferon Cytokine Res. 2014 Aug;34(8):605–614.
109. Y.Wang, S.Begum-Haque, K.M.Telesford, et al. A commensal bacterial product elicits and modulates migratory capacity of CD39(+) CD4 T regulatory subsets in the suppression of neuroinflammation. Gut Microbes. 2014 Jul 1;5(4):552–561.
110. H.K.Kwon, G.C.Kim, Y.Kim, et al. Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response. Clin Immunol. 2013 Mar;146(3):217–227.
111. J.Ochoa-Reparaz, D.W.Mielcarz, L.E.Ditrio, et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol. 2009 Nov 15;183(10):6041–6050.
112. Y.K.Lee, J.S.Menezes, Y.Umesaki, et al. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2011 Mar 15;108(Suppl 1):4615–4622.
113. K.Berer, M.Mues, M.Koutrolos, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 2011 Nov 24;479(7374):538–541.
114. S.Lavasani, B.Dzhambazov, M.Nouri, et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One. 2010;5(2):e9009.
115. J.Correale, M.Farez. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol. 2007 Feb;61(2):97–108.
116. M.Nouri, A.Bredberg, B.Westrom, et al. Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells. PLoS One. 2014;9(9):e106335.
117. L.Steinman. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol. 2014;32:257–281.• An excellent overview of the inflammatory aspects of the immunopathology of MS.
118. S.Jilek, M.Schluep, A.O.Rossetti, et al. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis. Clin Immunol. 2007 Apr;123(1):105–113.
119. M.Salou, B.Nicol, A.Garcia, et al. Involvement of CD8(+) T cells in multiple sclerosis. Front Immunol. 2015;6:604.
120. L.Szalardy, D.Zadori, M.Simu, et al. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. J Neurol Sci. 2013 Aug 15;331(1–2):38–42.
121. L.Cavone, B.Peruzzi, R.Caporale, et al. Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading. Br J Pharmacol. 2014 Mar;171(6):1501–1509.
122. T.F.Runia, W.C.Hop, Y.B.De Rijke, et al. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology. 2012 Jul 17;79(3):261–266.
123. S.Knippenberg, E.Peelen, J.Smolders, et al. Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission. J Neuroimmunol. 2011 Oct 28;239(1–2):80–86.
124. K.Cunnusamy, E.J.Baughman, J.Franco, et al. Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells. Clin Immunol. 2014 May-Jun;152(1–2):115–126.
125. J.M.Frischer, S.Bramow, A.Dal-Bianco, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain J Neurol. 2009 May;132(Pt 5):1175–1189.
126. J.Correale, M.Fiol, W.Gilmore. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006 Aug 22;67(4):652–659.
127. J.W.Prineas, E.E.Kwon, P.Z.Goldenberg, et al. Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest. 1989 Nov;61(5):489–503.
128. M.Podbielska, N.L.Banik, E.Kurowska, et al. Myelin recovery in multiple sclerosis:the challenge of remyelination. Brain Sci. 2013;3(3):1282–1324.
129. M.R.Kotter, W.W.Li, C.Zhao, et al. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci. 2006 Jan 4;26(1):328–332.
130. J.F.Bogie, W.Jorissen, J.Mailleux, et al. Myelin alters the inflammatory phenotype of macrophages by activating PPARs. Acta Neuropathol Commun. 2013;1:43.
131. M.P.Kurnellas, C.M.Adams, R.A.Sobel, et al. Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation. Sci Transl Med. 2013 Apr 3;5(179):179ra42.
132. J.M.Van Noort, M.Bsibsi, W.H.Gerritsen, et al. Alphab-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. J Neuropathol Exp Neurol. 2010 Jul;69(7):694–703.
133. J.M.Fletcher, R.Lonergan, L.Costelloe, et al. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol. 2009 Dec 1;183(11):7602–7610.
134. M.Ioannou, T.Alissafi, I.Lazaridis, et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol. 2012 Feb 1;188(3):1136–1146.
135. E.Peelen, J.Damoiseaux, J.Smolders, et al. Th17 expansion in MS patients is counterbalanced by an expanded CD39+ regulatory T cell population during remission but not during relapse. J Neuroimmunol. 2011 Dec 15;240–241:97–103.
136. M.H.Barnett, J.W.Prineas. Relapsing and remitting multiple sclerosis:pathology of the newly forming lesion. Ann Neurol. 2004 Apr;55(4):458–468.
137. M.H.Barnett, J.D.Parratt, J.D.Pollard, et al. MS:is it one disease? Int MS J/MS Forum. 2009 Jun;16(2):57–65.
138. M.H.Barnett, J.D.Parratt, E.S.Cho, et al. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol. 2009 Jan;65(1):32–46.
139. C.Lucchinetti, W.Bruck, J.Parisi, et al. Heterogeneity of multiple sclerosis lesions:implications for the pathogenesis of demyelination. Ann Neurol. 2000 Jun;47(6):707–717.
140. E.C.Breij, B.P.Brink, R.Veerhuis, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol. 2008 Jan;63(1):16–25.
141. B.Ferguson, M.K.Matyszak, M.M.Esiri, et al. Axonal damage in acute multiple sclerosis lesions. Brain J Neurol. 1997 Mar;120(Pt 3):393–399.
142. B.D.Trapp, J.Peterson, R.M.Ransohoff, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 Jan 29;338(5):278–285.
143. M.Calabrese, F.Agosta, F.Rinaldi, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol. 2009 Sep;66(9):1144–1150.
144. A.S.Nielsen, R.P.Kinkel, N.Madigan, et al. Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS. Neurology. 2013 Aug 13;81(7):641–649.
145. O.W.Howell, C.A.Reeves, R.Nicholas, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain J Neurol. 2011 Sep;134(Pt 9):2755–2771.
146. B.F.Popescu, C.F.Lucchinetti. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol. 2012;12:11.
147. A.Uccelli, F.Aloisi, V.Pistoia. Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol. 2005 May;26(5):254–259.
148. H.Lassmann, J.Van Horssen, D.Mahad. Progressive multiple sclerosis:pathology and pathogenesis. Nat Rev Neurol. 2012 Nov 5;8(11):647–656.• A wonderful review of progressive MS pathology.
149. M.T.Fischer, R.Sharma, J.L.Lim, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain J Neurol. 2012 Mar;135(Pt 3):886–899.
150. E.Gray, T.L.Thomas, S.Betmouni, et al. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett. 2008 Oct 24;444(2):195–198.
151. J.W.Prineas, E.E.Kwon, E.S.Cho, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. 2001 Nov;50(5):646–657.
152. M.Czeh, P.Gressens, A.M.Kaindl. The yin and yang of microglia. Dev Neurosci. 2011;33(3–4):199–209.
153. W.Gomes-Leal. Microglial physiopathology:how to explain the dual role of microglia after acute neural disorders? Brain Behav. 2012 May;2(3):345–356.
154. M.A.Friese, B.Schattling, L.Fugger. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 2014 Apr;10(4):225–238.
155. M.Bradl, H.Lassmann. Progressive multiple sclerosis. Semin Immunopathol. 2009 Nov;31(4):455–465.
156. R.Dutta, A.M.Chomyk, A.Chang, et al. Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors. Ann Neurol. 2013 May;73(5):637–645.
157. R.Magliozzi, B.Serafini, B.Rosicarelli, et al. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol. 2013 Jan;72(1):29–41.
158. L.Koh, A.Zakharov, M.Johnston. Integration of the subarachnoid space and lymphatics:is it time to embrace a new concept of cerebrospinal fluid absorption? Cerebrospinal Fluid Res. 2005 Sep 20;2:6.
159. R.J.Franklin, C.Ffrench-Constant. Remyelination in the CNS:from biology to therapy. Nat Rev Neurosci. 2008 Nov;9(11):839–855.
160. P.Patrikios, C.Stadelmann, A.Kutzelnigg, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain J Neurol. 2006;129(Pt 12):3165–3172.• An important paper highlighting the ongoing role of remyelination.
161. S.Bramow, J.M.Frischer, H.Lassmann, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain J Neurol. 2010 Oct;133(10):2983–2998.
162. J.M.Rodgers, A.P.Robinson, S.D.Miller. Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis. Discov Med. 2013 Aug;16(86):53–63.
163. B.Kornek, M.K.Storch, R.Weissert, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis:a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 2000 Jul;157(1):267–276.
164. M.Zawadzka, L.E.Rivers, S.P.Fancy, et al. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell. 2010 Jun 4;6(6):578–590.
165. H.O.Gautier, K.A.Evans, K.Volbracht, et al. Neuronal activity regulates remyelination via glutamate signalling to oligodendrocyte progenitors. Nat Commun. 2015;6:8518.
166. G.Wolswijk. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci. 1998 Jan 15;18(2):601–609.
167. G.R.John, S.L.Shankar, B.Shafit-Zagardo, et al. Multiple sclerosis:re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med. 2002 Oct;8(10):1115–1121.
168. G.R.Campbell, I.Ziabreva, A.K.Reeve, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol. 2011 Mar;69(3):481–492.
169. R.Dutta, J.McDonough, X.Yin, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006 Mar;59(3):478–489.
170. M.P.Murphy. How mitochondria produce reactive oxygen species. Biochem J. 2009 Jan 1;417(1):1–13.
171. E.Stephenson, N.Nathoo, Y.Mahjoub, et al. Iron in multiple sclerosis:roles in neurodegeneration and repair. Nat Rev Neurol. 2014 Aug;10(8):459–468.
172. F.D.Lublin, D.Miller, M.Freedman, et al. Oral fingolimod versus placebo in patients with primary progressive multiple sclerosis (PPMS):results of the INFORMS phase III trial. Aan. 2015 April 17;2015:2015.
173. K.Hawker, P.O’Connor, M.S.Freedman, et al. Rituximab in patients with primary progressive multiple sclerosis:results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 Oct;66(4):460–471.
174. J.S.Wolinsky, P.A.Narayana, P.O’Connor, et al. Glatiramer acetate in primary progressive multiple sclerosis:results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007 Jan;61(1):14–24.
175. Biogen. Biogen reports top-line results from Phase 3 study evaluating Natalizumab in secondary progressive MS. ASCEND Phase 3 trial did not meet primary and secondary endpoints; Natalizumab demonstrated statistically significant effect on upper limb function in patients [Internet]. Biogen; 2015. Available from:http://www.businesswire.com/news/home/20151021005273/en/Biogen-Reports-Top-Line-Results-Phase-3-Study
176. S.Grey Nee Cotte, A.Salmen Nee Stroet, N.Von Ahsen, et al. Lack of efficacy of mitoxantrone in primary progressive multiple sclerosis irrespective of pharmacogenetic factors:a multi-center, retrospective analysis. J Neuroimmunol. 2015 Jan 15;278:277–279.
177. A.Louveau, I.Smirnov, T.J.Keyes, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015 Jul 16;523(7560):337–341.
178. A.Aspelund, S.Antila, S.T.Proulx, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015 Jun 29;212(7):991–999.
179. K.Santana-de Anda, D.Gomez-Martin, M.Diaz-Zamudio, et al. Interferon regulatory factors:beyond the antiviral response and their link to the development of autoimmune pathology. Autoimmun Rev. 2011 Dec;11(2):98–103.
180. S.Dhib-Jalbut, S.Marks. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010 Jan 5;74(Suppl 1):S17–24.
181. V.S.Ramgolam, Y.Sha, K.L.Marcus, et al. B cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis. J Immunol. 2011 Apr 1;186(7):4518–4526.
182. J.J.Graber, C.A.McGraw, D.Kimbrough, et al. Overlapping and distinct mechanisms of action of multiple sclerosis therapies. Clin Neurol Neurosurg. 2010 Sep;112(7):583–591.
183. R.Aharoni, D.Teitelbaum, R.Arnon, et al. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):634–639.
184. P.W.Duda, M.C.Schmied, S.L.Cook, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000 Apr;105(7):967–976.
185. A.Prat, K.Biernacki, J.P.Antel. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1. J Autoimmun. 2005 Mar;24(2):119–124.
186. F.E.Durr, R.E.Wallace, R.V.Citarella. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev. 1983 Dec;10(Suppl B):3–11.
187. F.Martinelli Boneschi, L.Vacchi, M.Rovaris, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;5:Cd002127.
188. P.O’Connor. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther. 2007 Jan;7(1):123–136.
189. D.R.Jeffery, K.W.Rammohan, K.Hawker, et al. Fingolimod:a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis. Expert Rev Neurother. 2016 Jan;16(1):31–44.
190. A.Bar-Or, A.Pachner, F.Menguy-Vacheron, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014 Apr;74(6):659–674.
191. A S, K RR. Role of dimethyl fumarate in oxidative stress of multiple sclerosis:A review. J Chromatogr B. 2016 Apr 15;1019:15–20.
192. A.L.Cox, S.A.Thompson, J.L.Jones, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005 Nov;35(11):3332–3342.
193. G.A.Hill-Cawthorne, T.Button, O.Tuohy, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298–304.
194. F.Sellebjerg, M.Krakauer, S.Limborg, et al. Endogenous and recombinant type I interferons and disease activity in multiple sclerosis. PLoS One. 2012;7(6):e35927.
195. J.E.Martinez-Rodriguez, M.Lopez-Botet, E.Munteis, et al. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin Immunol. 2011 Dec;141(3):348–356.
196. M.F.Bustamante, N.Fissolo, J.Rio, et al. Implication of the Toll-like receptor 4 pathway in the response to interferon-beta in multiple sclerosis. Ann Neurol. 2011 Oct;70(4):634–645.
197. M.Comabella, J.D.Lunemann, J.Rio, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain J Neurol. 2009 Dec;132(Pt 12):3353–3365.
198. Y.Liu, R.Carlsson, M.Comabella, et al. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat Med. 2014 Mar;20(3):272–282.
199. C.Laske, P.Oschmann, J.Tofighi, et al. Prognostic value of soluble tumor necrosis factor receptors 1 and 2 in multiple sclerosis patients treated with interferon beta-1b. Eur Neurol. 2001;46(4):210–214.
200. D.Hesse, M.Krakauer, H.Lund, et al. Disease protection and interleukin-10 induction by endogenous interferon-beta in multiple sclerosis? EurOpean J Neurol. 2011 Feb;18(2):266–272.
201. J.J.Graber, D.Ford, M.Zhan, et al. Cytokine changes during interferon-beta therapy in multiple sclerosis:correlations with interferon dose and MRI response. J Neuroimmunol. 2007 Apr;185(1–2):168–174.
202. S.Dhib-Jalbut, S.Sumandeep, R.Valenzuela, et al. Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study. J Neuroimmunol. 2013 Jan 15;254(1–2):131–140.
203. M.F.Bustamante, R.N.Nurtdinov, J.Rio, et al. Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta. PLoS One. 2013;8(4):e60994.
204. R.Aharoni, B.Kayhan, R.Eilam, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14157–14162.
205. M.Chen, R.M.Valenzuela, S.Dhib-Jalbut. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci. 2003 Nov 15;215(1–2):37–44.
206. D.M.McTigue, P.J.Horner, B.T.Stokes, et al. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci. 1998 Jul 15;18(14):5354–5365.
207. P.L.Vieira, H.C.Heystek, J.Wormmeester, et al. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol. 2003 May 1;170(9):4483–4488.
208. C.Chen, X.Liu, B.Wan, et al. Regulatory properties of copolymer I in Th17 differentiation by altering STAT3 phosphorylation. J Immunol. 2009 Jul 1;183(1):246–253.
209. A.Sanna, M.L.Fois, G.Arru, et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol. 2006 Feb;143(2):357–362.
210. R.Allie, L.Hu, K.M.Mullen, et al. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch Neurol. 2005 Jun;62(6):889–894.
211. J.Liu, T.V.Johnson, J.Lin, et al. T cell independent mechanism for copolymer-1-induced neuroprotection. Eur J Immunol. 2007 Nov;37(11):3143–3154.
212. M.S.Weber, T.Prod’homme, S.Youssef, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med. 2007 Aug;13(8):935–943.
213. M.Kala, S.N.Rhodes, W.H.Piao, et al. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol. 2010 Jan;221(1):136–145.
214. K.L.Sand, E.Knudsen, J.Rolin, et al. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci. 2009 Apr;66(8):1446–1456.
215. M.Rieks, V.Hoffmann, O.Aktas, et al. Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate. Eur Neurol. 2003;50(4):200–206.
216. J.Hong, N.Li, X.Zhang, et al. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A. 2005 May 3;102(18):6449–6454.
217. N.J.Karandikar, M.P.Crawford, X.Yan, et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest. 2002 Mar;109(5):641–649.
218. C.Farina, F.Then Bergh, H.Albrecht, et al. Treatment of multiple sclerosis with Copaxone (COP):elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain J Neurol. 2001 Apr;124(Pt 4):705–719.
219. C.Iarlori, D.Gambi, A.Lugaresi, et al. Reduction of free radicals in multiple sclerosis:effect of glatiramer acetate (Copaxone). Mult Scler. 2008 Jul;14(6):739–748.
220. M.Krumbholz, I.Meinl, T.Kumpfel, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008 Oct 21;71(17):1350–1354.
221. O.Stuve, C.M.Marra, K.R.Jerome, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006 May;59(5):743–747.
222. M.Niino, C.Bodner, M.L.Simard, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol. 2006 May;59(5):748–754.
223. C.Warnke, M.Stettner, V.Lehmensiek, et al. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Mult Scler. 2015 Jul;21(8):1036–1044.
224. R.Mancuso, D.Franciotta, M.Rovaris, et al. Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients:a longitudinal study. Mult Scler. 2014 Dec;20(14):1900–1903.
225. A.Harrer, H.Tumani, S.Niendorf, et al. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler. 2013 Aug;19(9):1209–1212.
226. G.Bloomgren, S.Richman, C.Hotermans, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 May 17;366(20):1870–1880.
227. T.Plavina, M.Subramanyam, G.Bloomgren, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014 Dec;76(6):802–812.
228. J.Bauer, R.Gold, O.Adams, et al. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS). Acta Neuropathol. 2015 Dec;130(6):751–764.
229. V.Limmroth, F.Barkhof, N.Desem, et al. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology. 2014 Nov 11;83(20):1780–1788.
230. E.Havrdova, J.A.Cohen, D.A.S.Compston, et al. Coles, on behalf of the CARE-MS I investigators. In:Durable efficacy of alemtuzumab on clinical outcomes over 5 years in treatment-naive patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years:CARE-MS I extension study. Barcelona:ECTRIMS; 2015.
231. X.Zhang, Y.Tao, M.Chopra, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013 Dec 15;191(12):5867–5874.
232. J.L.Jones, C.L.Phuah, A.L.Cox, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009 Jul;119(7):2052–2061.
233. L.Isidoro, P.Pires, L.Rito, et al. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep. 2014 Jan 8. doi:10.1136/bcr-2013-201781. [Epub ahead of print].
234. M.Mehling, V.Brinkmann, J.Antel, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008 Oct 14;71(16):1261–1267.
235. Y.Miyazaki, M.Niino, T.Fukazawa, et al. Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations. Clin Immunol. 2014 Apr;151(2):127–135.
236. C.A.Foster, D.Mechtcheriakova, M.K.Storch, et al. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis:expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 2009 Apr;19(2):254–266.
237. K.Selmaj, D.K.Li, H.P.Hartung, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD):an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013 Aug;12(8):756–767.
238. L.Kappos, A.Bar-Or, J.Camm, et al. Results of MOMENTUM, a randomised, double-blind, placebo-controlled, phase 2 trial with MT-1303, a novel selective sphingosine 1-phosphate receptor 1 (S1P1) modulator, in relapsing-remitting MS. Barcelona, Spain:ECTRIMS; 2015.
239. A.M.Subei, J.A.Cohen. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs. 2015 Jul;29(7):565–575.
240. A.Chan, J.De Seze, M.Comabella. Teriflunomide in patients with relapsing-remitting forms of multiple sclerosis. CNS Drugs. 2016 Jan 12;30:41–51.
241. M.Zeyda, M.Poglitsch, R.Geyeregger, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide:involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 2005 Sep;52(9):2730–2739.
242. K.Itoh, T.Chiba, S.Takahashi, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997 Jul 18;236(2):313–322.
243. X.L.Chen, G.Dodd, S.Thomas, et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circulatory Physiol. 2006 May;290(5):H1862–70.
244. V.Calabrese, A.Ravagna, C.Colombrita, et al. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress:involvement of the transcription factor Nrf2. J Neurosci Res. 2005 Feb 15;79(4):509–521.
245. J.Li, D.Johnson, M.Calkins, et al. Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci. 2005 Feb;83(2):313–328.
246. M.S.Brennan, H.Patel, N.Allaire, et al. Pharmacodynamics of dimethyl fumarate are tissue-specific and involve NRF2-dependent and -independent mechanisms. Antioxid Redox Signal. 2016 Mar 16 doi:10.1089/ars.2015.6622. [Epub ahead of print].
247. B.Parodi, S.Rossi, S.Morando, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol. 2015 Aug;130(2):279–295.
248. U.Schulze-Topphoff, M.Varrin-Doyer, K.Pekarek, et al. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4777–4782.
249. F.Treumer, K.Zhu, R.Glaser, et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003 Dec;121(6):1383–1388.
250. Y.Kihara, A.Groves, R.R.Rivera, et al. Dimethyl fumarate inhibits integrin alpha4 expression in multiple sclerosis models. Annals Clin Transl Neurol. 2015 Oct;2(10):978–983.
251. D.J.Nieuwkamp, J.L.Murk, B.W.Van Oosten, et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med. 2015 Apr 9;372(15):1474–1476.
252. A.Poli, T.Michel, M.Theresine, et al. CD56bright natural killer (NK) cells:an important NK cell subset. Immunology. 2009 Apr;126(4):458–465.
253. J.S.Yang, L.Y.Xu, B.G.Xiao, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol. 2004 Nov;156(1–2):3–9.
254. W.Bruck, C.Wegner. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011 Jul 15;306(1–2):173–179.
255. S.L.Hauser, H.-P.Hartung, K.Selmaj, et al. Kappos, on behalf of the OPERA I and II clinical investigators Efficacy and safety of ocrelizumab in relapsing multiple sclerosis - results of the interferon-beta-1a-controlled, double-blind, Phase III OPERA I and II studies. Barcelona, Spain:ECTRIMS; 2015.
256. P.S.Sorensen, S.Lisby, R.Grove, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis:a phase 2 study. Neurology. 2014 Feb 18;82(7):573–581.
257. R.Gonsette, M.Debouverie, C.Sindic, et al. Pixantrone:a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease. Mult Scler. 2016 May;22(6):817–821.
258. Y.Ramot, M.Rosenstock, E.Klinger, et al. Comparative long-term preclinical safety evaluation of two glatiramoid compounds (glatiramer Acetate, Copaxone(R), and TV-5010, protiramer) in rats and monkeys. Toxicol Pathol. 2012;40(1):40–54.
259. N.De Stefano, M.Filippi, C.Confavreux, et al. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2009 Feb;15(2):238–243.
260. Adis International Limited. Temsirolimus:CCI 779, CCI-779, cell cycle inhibitor-779. Drugs R D. 2004;5(6):363–367.
261. S.L.Hauser, E.Waubant, D.L.Arnold, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14;358(7):676–688.•• This study strongly supports and garnered serious attention toward the role of B cells in MS pathophysiology.
262. N.S.Vermeer, S.M.Straus, A.K.Mantel-Teeuwisse, et al. Drug-induced progressive multifocal leukoencephalopathy:lessons learned from contrasting natalizumab and rituximab. Clin Pharmacol Ther. 2015 Nov;98(5):542–550.
263. M.Agius, M.Maciejowski, A.Potemkowski, et al. Safety and tolerability of MEDI-551 in patients with relapsing forms of multiple sclerosis:results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Barcelona, Spain:ECTRIMS; 2015 Oct 8.
264. D.Chen, M.Blazek, S.Ireland, et al. Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms. J Immunol. 2014 Nov 15;193(10):4823–4832.
265. E.Klimatcheva, T.Pandina, C.Reilly, et al. CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol. 2015;16:6.
266. L.Kappos, H.P.Hartung, M.S.Freedman, et al. Atacicept in multiple sclerosis (ATAMS):a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014 Apr;13(4):353–363.
267. J.C.Edwards, G.Cambridge. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006 May;6(5):394–403.
268. F.E.Lund, T.D.Randall. Effector and regulatory B cells:modulators of CD4+ T cell immunity. Nat Rev Immunol. 2010 Apr;10(4):236–247.
269. M.Yang, L.Sun, S.Wang, et al. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol. 2010 Apr 1;184(7):3321–3325.
270. C.T.Harp, S.Ireland, L.S.Davis, et al. Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol. 2010 Oct;40(10):2942–2956.
271. F.Luhder, R.Gold. Trial and error in clinical studies:lessons from ATAMS. Lancet Neurol. 2014 Apr;13(4):340–341.
272. Eli Lilly to discontinue development of tabalumab due to insufficient efficacy in Phase 3 Lupus trials. Medicine NM-LS, ed. [Internet]. Available from:http://www.news-medical.net/2014.
273. G.Vlad, E.K.Ho, E.R.Vasilescu, et al. Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol. 2007 Jul;18(1):13–21.
274. B.Bielekova. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013 Jan;10(1):55–67.
275. D.Wynn, M.Kaufman, X.Montalban, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study):a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 Apr;9(4):381–390.
276. R.Gold, G.Giovannoni, K.Selmaj, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT):a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22;381(9884):2167–2175.
277. C.Wegner, C.Stadelmann, R.Pfortner, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010 Oct 8;227(1–2):133–143.
278. C.Kolb-Sobieraj, S.Gupta, B.Weinstock-Guttman. Laquinimod therapy in multiple sclerosis:a comprehensive review. Neurol Ther. 2014 Jun;3(1):29–39.
279. E.Toubi, S.Nussbaum, E.Staun-Ram, et al. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J Neuroimmunol. 2012 Oct 15;251(1–2):45–54.
280. W.Bruck, R.Pfortner, T.Pham, et al. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411–424.
281. V.Jolivel, F.Luessi, J.Masri, et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain J Neurol. 2013 Apr;136(Pt 4):1048–1066.
282. U.Schulze-Topphoff, A.Shetty, M.Varrin-Doyer, et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One. 2012;7(3):e33797.
283. J.Thone, G.Ellrichmann, S.Seubert, et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol. 2012 Jan;180(1):267–274.
284. M.K.Mishra, J.Wang, M.B.Keough, et al. Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Annals Clin Transl Neurol. 2014 Jun;1(6):409–422.
285. G.Comi, D.Jeffery, L.Kappos, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012 Mar 15;366(11):1000–1009.
286. T.L.Vollmer, P.S.Sorensen, K.Selmaj, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014 Apr;261(4):773–783.
287. TNF neutralization in MS:results of a randomized, placebo-controlled multicenter study. The lenercept multiple sclerosis study group and The University of British Columbia MS/MRI analysis group. Neurology. 1999 Aug 11;53(3):457–465.
288. T.L.Vollmer, D.R.Wynn, M.S.Alam, et al. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and −23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler. 2011 Feb;17(2):181–191.
289. B.W.Van Oosten, F.Barkhof, L.Truyen, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996 Dec;47(6):1531–1534.
290. R.Brambilla, J.J.Ashbaugh, R.Magliozzi, et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain J Neurol. 2011 Sep;134(Pt 9):2736–2754.
291. C.S.Constantinescu, A.Asher, W.Fryze, et al. Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurology Neuroimmunol Neuroinflamm. 2015 Aug;2(4):e117.
292. M.C.Genovese, P.Durez, H.B.Richards, et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis:phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol. 2014 Mar;41(3):414–421.
293. W.Hueber, B.E.Sands, S.Lewitzky, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease:unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693–1700.
294. B.M.Segal, C.S.Constantinescu, A.Raychaudhuri, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis:a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008 Sep;7(9):796–804.
295. S.Serada, M.Fujimoto, M.Mihara, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9041–9046.
296. B.Bielekova, R.Martin. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med (Berl). 2001 Oct;79(10):552–565.
297. S.Mi, R.B.Pepinsky, D.Cadavid. Blocking LINGO-1 as a therapy to promote CNS repair:from concept to the clinic. CNS Drugs. 2013 Jul;27(7):493–503.
298. M.A.Liu. DNA vaccines:a review. J Intern Med. 2003 Apr;253(4):402–410.
299. J.Correale, M.Fiol. BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis. Curr Opin Mol Ther. 2009 Aug;11(4):463–470.
300. F.Sedel, D.Bernard, D.M.Mock, et al. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology. 2015 Sep 5:pii:S0028-3908(15)30073-3. doi:10.1016/j.neuropharm.2015.08.028. [Epub ahead of print]•• Exciting potential new therapy for remyelination.
301. G.W.Hassen, J.Feliberti, L.Kesner, et al. Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. Brain Res. 2008 Oct;21(1236):206–215.
302. J.R.Podojil, S.D.Miller. Targeting the B7 family of co-stimulatory molecules:successes and challenges. BioDrugs. 2013 Feb;27(1):1–13.
303. K.G.Warren, I.Catz, L.Z.Ferenczi, et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis:results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. EurOpean J Neurol. 2006 Aug;13(8):887–895.
304. O.Aktas, T.Prozorovski, A.Smorodchenko, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol. 2004 Nov 1;173(9):5794–5800.
305. A.Mangas, R.Covenas, D.Bodet, et al. A new drug candidate (GEMSP) for multiple sclerosis. Curr Med Chem. 2009;16(25):3203–3214.
306. P.Rolan, M.Hutchinson, K.Johnson. Ibudilast:a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother. 2009 Dec;10(17):2897–2904.
307. T.Fujimoto, S.Sakoda, H.Fujimura, et al. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol. 1999 Mar 1;95(1–2):35–42.
308. N.Gueven, K.Woolley, J.Smith. Border between natural product and drug:comparison of the related benzoquinones idebenone and coenzyme Q10. Redox Biol. 2015;4:289–295.
309. V.Yadav, G.Marracci, J.Lovera, et al. Lipoic acid in multiple sclerosis:a pilot study. Mult Scler. 2005 Apr;11(2):159–165.
310. V.W.Yong, J.Wells, F.Giuliani, et al. The promise of minocycline in neurology. Lancet Neurol. 2004 Dec;3(12):744–751.
311. F.D.Shi, W.H.Piao, Y.P.Kuo, et al. Nicotinic attenuation of central nervous system inflammation and autoimmunity. J Immunol. 2009 Feb 1;182(3):1730–1739.
312. J.A.Black, S.G.Waxman. Phenytoin protects central axons in experimental autoimmune encephalomyelitis. J Neurol Sci. 2008 Nov 15;274(1–2):57–63.
313. C.B.Maassen, E.Claassen. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. Vaccine. 2008 Apr 16;26(17):2056–2057.
314. P.J.Van Der Most, A.M.Dolga, I.M.Nijholt, et al. Statins:mechanisms of neuroprotection. Prog Neurobiol. 2009 May;88(1):64–75.
315. A.A.Vandenbark, N.E.Culbertson, R.M.Bartholomew, et al. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology. 2008 Jan;123(1):66–78.
316. F.J.Quintana, I.R.Cohen. Anti-ergotypic immunoregulation. Scand J Immunol. 2006 Sep;64(3):205–210.
317. M.Hultqvist, K.S.Nandakumar, U.Bjorklund, et al. The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders. Ann Rheum Dis. 2009 Jan;68(1):130–135.
318. I.Lavrnja, D.Stojkov, I.Bjelobaba, et al. Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production. Int Immunopharmacol. 2008 Sep;8(9):1282–1290.
319. B.W.Van Oosten, M.Lai, S.Hodgkinson, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412:results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology. 1997 Aug;49(2):351–357.
320. J.W.Lindsey, S.Hodgkinson, R.Mehta, et al. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol. 1994 Aug;36(2):183–189.
321. J.W.Lindsey, S.Hodgkinson, R.Mehta, et al. Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology. 1994 Mar;44(3 Pt 1):413–419.
322. K.W.Wucherpfennig, I.Catz, S.Hausmann, et al. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest. 1997 Sep 1;100(5):1114–1122.
323. G.G.Burrows, R.Meza-Romero, J.Huan, et al. Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis. Metab Brain Dis. 2012 Jun;27(2):143–149.
324. S.Sinha, S.Subramanian, L.Miller, et al. Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand. J Neurosci. 2009 Mar 25;29(12):3816–3823.
325. S.Sinha, L.Miller, S.Subramanian, et al. Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010 Aug 25;225(1–2):52–61.
326. V.Yadav, D.N.Bourdette, J.D.Bowen, et al. Recombinant T-cell Receptor Ligand (RTL) for treatment of multiple sclerosis:a double-blind, placebo-controlled, Phase 1, dose-escalation study. Autoimmune Dis. 2012;2012:954739.
327. H.Offner, S.Sinha, G.G.Burrows, et al. RTL therapy for multiple sclerosis:a Phase I clinical study. J Neuroimmunol. 2011 Feb;231(1–2):7–14.
328. R.Medaer, P.Stinissen, L.Truyen, et al. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination:pilot trial in multiple sclerosis. Lancet. 1995 Sep 23;346(8978):807–808.
329. J.Zhang. T-cell vaccination for autoimmune diseases:immunologic lessons and clinical experience in multiple sclerosis. Expert Rev Vaccines. 2002 Oct;1(3):285–292.
330. J.Z.Zhang, V.M.Rivera, M.V.Tejada-Simon, et al. T cell vaccination in multiple sclerosis:results of a preliminary study. J Neurol. 2002 Feb;249(2):212–218.
331. B.Loftus, B.Newsom, M.Montgomery, et al. Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies. Clin Immunol. 2009 May;131(2):202–215.
332. N.Hellings, J.Raus, P.Stinissen. T-cell vaccination in multiple sclerosis:update on clinical application and mode of action. Autoimmun Rev. 2004 Jun;3(4):267–275.
333. A.Achiron, M.Mandel. T-cell vaccination in multiple sclerosis. Autoimmun Rev. 2004 Jan;3(1):25–32.
334. A.A.Vandenbark, R.Abulafia-Lapid. Autologous T-cell vaccination for multiple sclerosis:a perspective on progress. BioDrugs. 2008;22(4):265–273.
335. D.Karussis, H.Shor, J.Yachnin, et al. T cell vaccination benefits relapsing progressive multiple sclerosis patients:a randomized, double-blind clinical trial. PLoS One. 2012;7(12):e50478.
336. A.A.Vandenbark, Y.K.Chou, R.Whitham, et al. Treatment of multiple sclerosis with T-cell receptor peptides:results of a double-blind pilot trial. Nat Med. 1996 Oct;2(10):1109–1115.
337. V.Viglietta, K.Bourcier, G.J.Buckle, et al. CTLA4Ig treatment in patients with multiple sclerosis:an open-label, phase 1 clinical trial. Neurology. 2008 Sep 16;71(12):917–924.
338. C.E.Smith, T.N.Eagar, J.L.Strominger, et al. Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9595–9600.
339. A.Lutterotti, S.Yousef, A.Sputtek, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells:a phase 1 trial in multiple sclerosis. Sci Transl Med. 2013 Jun 5;5(188):188ra75.
340. P.Peschl, M.Reindl, K.Schanda, et al. Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells. Mult Scler. 2015 Apr;21(5):651–655.
341. Z.Hunter, D.P.McCarthy, W.T.Yap, et al. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano. 2014 Mar 25;8(3):2148–2160.
342. H.Garren. A DNA vaccine for multiple sclerosis. Expert Opin Biol Ther. 2008 Oct;8(10):1539–1550.
343. A.M.Faria, H.L.Weiner. Oral tolerance:therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006 Jun-Dec;13(2–4):143–157.
344. L.Kappos, F.Barkhof, A.Desmet, et al. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis:results from a randomized controlled clinical trial [abstract 158]. J Neurol. 2005;252(Suppl 2):46.
345. L.M.Metz, Y.Zhang, M.Yeung, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol. 2004 May;55(5):756.
346. L.M.Metz, D.Li, A.Traboulsee, et al. Glatiramer acetate in combination with minocycline in patients with relapsing–remitting multiple sclerosis:results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler. 2009 Oct;15(10):1183–1194.
347. L.M.Metz, A.Traboulsee, P.Duquette, et al. Minocycline reduces the relative risk of multiple sclerosis in people experiencing their first clinical demyelinating event by 44.6%:results of a phase III double-blind placebo controlled Canadian multicentre clinical trial. Barcelona, Spain:ECTRIMS; 2015.
348. M.Geffard, S.Duleu, A.Bessede, et al. GEMSP:a new therapeutic approach to multiple sclerosis. Cent Nerv Syst Agents Med Chem. 2012 Sep;12(3):173–181.
349. O.Aktas, G.Comi, T.Ziemssen, et al. Cadavid, on behalf of the RENEW investigators anti-LINGO-1 monoclonal antibody BIIB033 improves optic nerve latency in acute optic neuritis:primary efficacy analysis of the RENEW study. Barcelona:ECTRIMS; 2015.
350. M.Diego Cadavid, L.Balcer, S.Galetta, et al. Evidence of remyelination with the anti-LINGO-1 monoclonal antibody BIIB033 after acute optic neuritis. Washington (DC):AAN; 2015.
351. G.Piaton, M.S.Aigrot, A.Williams, et al. Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Brain J Neurol. 2011 Apr;134(Pt 4):1156–1167.
352. V.K.Harris, S.A.Sadiq. Stem cell therapy in multiple sclerosis:a future perspective. Neurodegener Dis Manag. 2015;5(3):167–170.
353. G.L.Mancardi, M.P.Sormani, F.Gualandi, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis:a phase II trial. Neurology. 2015 Mar 10;84(10):981–988.
354. S.Llufriu, M.Sepulveda, Y.Blanco, et al. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One. 2014;9(12):e113936.
355. R.Ali, S.Marley, S.Mallik, et al. Preliminary results of a phase 2 trial of autologous mesenchymal cell therapy in MS (STREAMS). Barcelona, Spain:ECTRIMS; 2015 Sep 23.
356. T.Gharibi, M.Ahmadi, N.Seyfizadeh, et al. Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis. Cell Immunol. 2015 Feb;293(2):113–121.
357. F.D.Lublin, J.D.Bowen, J.Huddlestone, et al. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis:a randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord. 2014 Nov;3(6):696–704.
358. C.M.Rice, D.I.Marks, Y.Ben-Shlomo, et al. Assessment of bone marrow-derived cellular therapy in progressive multiple sclerosis (ACTiMuS):study protocol for a randomised controlled trial. Trials. 2015;16(1):463.
359. D.A.Bechtold, X.Yue, R.M.Evans, et al. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain J Neurol. 2005 Jan;128(Pt 1):18–28.
360. A.C.Lo, C.Y.Saab, J.A.Black, et al. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol. 2003 Nov;90(5):3566–3571.
361. D.A.Bechtold, S.J.Miller, A.C.Dawson, et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol. 2006 Dec;253(12):1542–1551.
362. R.Kapoor, J.Furby, T.Hayton, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis:a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010 Jul;9(7):681–688.
363. T.Hayton, J.Furby, K.J.Smith, et al. Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis:data from a randomised placebo controlled trial of lamotrigine. J Neurol. 2012 Mar;259(3):505–514.
364. B.Breuer, M.Pappagallo, H.Knotkova, et al. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther. 2007 Sep;29(9):2022–2030.
365. R.Kapoor, R.Raftopoulos, S.Hickman, et al. Phenytoin is neuroprotective in acute optic neuritis:results of a phase 2 randomized controlled trial. The 67th annual meeting of the American Academy of Neurology; 2015Apr18–25; Washington, DC.
366. J.Y.Lee, E.Cho, Y.E.Ko, et al. Ibudilast, a phosphodiesterase inhibitor with anti-inflammatory activity, protects against ischemic brain injury in rats. Brain Res. 2012 Jan 11;1431:97–106.
367. F.Barkhof, H.E.Hulst, J.Drulovic, et al. Ibudilast in relapsing-remitting multiple sclerosis:a neuroprotectant? Neurology. 2010 Mar 30;74(13):1033–1040.
368. F.Sedel, C.Papeix, A.Bellanger, et al. High doses of biotin in chronic progressive multiple sclerosis:a pilot study. Mult Scler Relat Disord. 2015 Mar;4(2):159–169.
369. A.Tourbah, C.Lebrun-Frenay, G.Edan, et al. Effect of MD1003 (high doses of biotin) in progressive multiple sclerosis:results of a pivotal phase III randomized double blind placebo controlled study (PL2.002). MD1003 shows promise for secondary, primary progressive multiple sclerosis:presented at AAN; 2015 Apr 25; Washington, DC.
370. M.H.Parkinson, J.B.Schulz, P.Giunti. Co-enzyme Q10 and idebenone use in Friedreich’s ataxia. J Neurochem. 2013 Aug;126(Suppl 1):125–141.
371. G.M.Buyse, T.Voit, U.Schara, et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS):a double-blind randomised placebo-controlled phase 3 trial. Lancet. 2015 May 2;385(9979):1748–1757.
372. T.Vollmer, L.Key, V.Durkalski, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004 May 15;363(9421):1607–1608.
373. A.Tsakiri, K.Kallenbach, D.Fuglo, et al. Simvastatin improves final visual outcome in acute optic neuritis:a randomized study. Mult Scler. 2012 Jan;18(1):72–81.
374. J.Chataway, N.Schuerer, A.Alsanousi, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT):a randomised, placebo-controlled, phase 2 trial. Lancet. 2014 Jun 28;383(9936):2213–2221.
375. P.De Sarno, R.C.Axtell, C.Raman, et al. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol. 2008 Jul 1;181(1):338–345.
376. Q.Sun, Y.Zheng, X.Zhang, et al. Novel immunoregulatory properties of EGCG on reducing inflammation in EAE. Frontiers Biosci. 2013;18:332–342.
377. F.D.Lublin, S.S.Cofield, G.R.Cutter, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013 Mar;73(3):327–340.
378. R.R.Voskuhl, H.Wang, T.C.Wu, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis:a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jan;15(1):35–46.
379. P.S.Sorensen, F.Sellebjerg, J.Lycke, et al. Minocycline added to subcutaneous interferon beta-1a in multiple sclerosis:randomized RECYCLINE study. Eur J Neurol. 2016 May;23(5):861–870.